Follow that botanical: Challenges and recommendations for assessing absorption, distribution, metabolism and excretion of botanical dietary supplements

Food and Chemical Toxicology

Volumn 121, Issue , 2018, Pages 194-202

  Waidyanatha, Suramya ^a   Ryan, Kristen ^a   Roe, Amy L ^b   Jia, Wei ^c   Paine, Mary F ^d   Ferguson, Stephen ^a   Gurley, Bill J ^e   Welch, Kevin ^f   Chow, Moses S S ^g   Devito, Michael ^a   Rider, Cynthia ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b PROCTER AND GAMBLE COMPANY   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f U S DEPARTMENT OF AGRICULTURE   (United States)

^g WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

ADME; Botanical dietary supplements; Botanical drug interaction; Ginkgo biloba extract; Pharmacokinetics; Poly pharmacokinetics; Toxicokinetics

Indexed keywords

GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; PHYTOCHEMICAL; PLANT EXTRACT; XENOBIOTIC AGENT;

ARTICLE; BIOLOGICAL ACTIVITY; CASE STUDY; DIETARY SUPPLEMENT; DNA FINGERPRINTING; DRUG ABSORPTION; DRUG ANALYSIS; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INTERACTION; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHYTOCHEMISTRY; ANIMAL; HERB DRUG INTERACTION;

ANIMALS; DIETARY SUPPLEMENTS; HERB-DRUG INTERACTIONS; HUMANS; PHYTOCHEMICALS; PLANT EXTRACTS; XENOBIOTICS;

EID: 85051210320     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2018.08.062     Document Type: Article

References (88)

1. Abad, M.J., Bedoya, L.M., Bermejo, P., An update on drug interactions with the herbal medicine. Ginkgo biloba. Curr. Drug Metabol. 11 (2010), 171–181.
2. Barnes, P.M., Bloom, B., Nahin, R.L., Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 12 (2008), 1–23.
3. Barrett, B., Medicinal properties of Echinacea: a critical review. Phytomedicine 1 (2003), 66–86.
4. Behl, M., Nyska, A., Chabara, R.S., Travlos, G.S., Fomby, L.M., Sparrow, B.R., Hejtmancik, M.R., Chan, P., Liver toxicity and carcinogenicity in F344/N rats and B6C3F1 mice exposed to kava kava. Food Chem. Toxicol. 49:11 (2011), 2820–2829.
5. Benzie, I.F.F., Wachttel-Galor, S., Herbal Medicine, Biomolecular and Clinical Aspects, 2011. second ed., 2011, CRC Press/Taylor & Francis (ISBN-13: 978-1-4398-0713-2).
6. Bereczki, D., Fekete, I., Vinpocetine for acute ischemic stroke. Cochrane Database Syst. Rev., 1, 2008 CD000580.
7. Biber, A., Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry 36:Suppl. 1 (2003), S32–S37.
8. Biber, A., Koch, E., Bioavailability of ginkgolides and bilobalide from extracts of ginkgo biloba using GC/MS. Planta Med. 65:2 (1999), 192–193.
9. Brantley, S.J., Oberlies, N.H., Kroll, D.J., Paine, M.F., Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J. Pharmacol. Exp. Therapeut. 332:3 (2010), 1081–1087.
10. Brantley, S.J., Graf, T.N., Oberlies, N.H., Paine, M.F., A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. Drug Metab. Dispos. 41:9 (2013), 1662–1670.
11. Brantley, S.J., Argikar, A.A., Lin, Y.S., Nagar, S., Paine, M.F., Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab. Dispos. 42:3 (2014), 301–317.
12. Brinkley, T.E., Lovato, J.F., Arnold, A.M., Furberg, C.D., Kuller, L.H., Burke, G.L., Nahin, R.L., Lopez, O.L., Yasar, S., Williamson, J.D., Effect of ginkgo biloba on blood pressure and incidence of hypertension in elderly men and women. Am. J. Hypertens. 23 (2010), 528–533.
13. Catlin, N.R., Collins, B., Auerbach, S.S., Ferguson, S.S., Harnly, J., Gennins, C., Waidyanatha, S., Rice, G., Smith-Roe, S.L., Witt, K.L., Rider, C.V., How similar is similar enough? A sufficient similarity case study with ginkgo biloba extract. Food Chem. Toxicol. 118 (2018), 328–339.
14. Catlin, N.R., Waidyanatha, S., Mylchreest, E., Miller, L., Cunny, H., Foster, P., Sutherland, S., McIntyre, B.S., Embryo-fetal development studies with the dietary supplement vipocetine in the rat and rabbit. Birth Defects Res. Part B: Dev. Reproductive Toxicol. 110 (2018), 883–896.
15. Chen, X.W., Sneed, K.B., Pan, S.Y., Cao, C.H., Kanwar, J.R., Chew, H., Zhou, S.F., Herb-drug interactions and mechanistic and clinical considerations. Curr. Drug Metabol. 13 (2012), 640–651.
16. Chen, S., Wan, L., Couch, L., Lin, H., Li, Y., Dobrovolsky, V.N., Mei, N., Guo, L., Mechanism study of goldenseal-associated DNA damage. Toxicol. Lett. 221:1 (2013), 64–72.
17. Cheng, F., Li, L., Xu, F., Sun, Y., Du, F., Ma, X., Zhong, C., Li, X., Wang, F., Zhang, N., Li, C., Systemic and cerebral exposure to and pharmacokinetics of flavonols and terpene lactones after dosing standardized Ginkgo biloba leaf extracts to rats via different routes of admistration. Britsh J. Pharm. 170 (2013), 440–457.
18. Clarke, T.C., Black, L.I., Stussman, B.J., Barnes, P.M., Nahin, R.L., Trends in the use of complementary health approaches among adults: United States, 2002-2012. Natl. Health. Stat. Rep. 79 (2015), 1–16.
19. Clewell, H.J. III, Anderson, M.E., Risk assessment extrapolations and physiological modeling. Toxicol. Ind. Health 4 (1985), 111–131.
20. deFeudis, F.V., A brief history of EGb761 and its therapeutic uses. Pharmacopsychiatry 36 (2003), S2–S7.
21. DeKosky, S.T., Williamson, J.D., Fitzpatrick, A.L., Kronmal, R.A., Ives, D.G., Saxton, J.A., Lopez, O.L., Burke, G., Carlson, M.C., Fried, L.P., Kuller, L.H., Robbins, J.A., Tracy, R.P., Woolard, N.F., Dunn, L., Snitz, B.E., Nahin, R.L., Furberg, C.D., Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for prevention of dementia: a randomized controlled trial. J. Am. Med. Assoc., 300, 2008, 2730.
22. Drago, F., Floriddia, M.L., Cro, M., Giuffrida, S., Pharmacokinetics and bioavailability of a Ginkgo biloba extract. J. Ocul. Pharmacol. Therapeut. 18:2 (2002), 197–202.
23. Dunnick, J.K., Kissling, G., Gerken, D.K., Vallant, M.A., Nyska, A., Cardiotoxicity of Ma Huang/caffeine or ephedrine/caffeine in a rodent model system. Toxicol. Pathol. 35:5 (2007), 657–664.
24. Foster, S., Black cohosh: a literature review. Herbalgram. Winter, 1999, 35–49.
25. Fourtillan, J.B., Brisson, A.M., Girault, J., Ingrand, I., Decourt, J.P., Drieu, K., Jouenne, P., Biber, A., Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb761). Therapie 50:2 (1995), 137–144.
26. Fransen, H.P., Pelgrom, S.M., Stewart-Knox, B., de Kaste, D., Verhagen, H., Assessment of health claims, content, and safety of herbal supplements containing Ginkgo biloba. Food Nutr. Res., 30, 2010, 54.
27. Gufford, B.T., Chen, G., Vergara, A.G., Lazarus, P., Oberlies, N.H., Paine, M.F., Milk thistle constituents inhibit raloxifene intestinal glucuronidation: a potential clinically relevant natural product-drug interaction. Drug Metab. Dispos. 43:9 (2015), 1353–1359.
28. Gufford, B.T., Bard, J.T., Gonzalez-Perez, V., Layton, M.E., White, J.R. Jr., Oberlies, N.H., Paine, M.F., Quantitative prediction and clinical evalution of an unexplored herb-drug interacton mechanism in healthy volunteers. CPT Pharmacometrics Syst. Pharmacol. 4:12 (2015), 701–710.
29. Gurley, B.J., Pharmacokinetic herb-drug interactions (Part 1): origins, mechansims, and the impact of botanical dietary supplements. Planta Med. 78:13 (2012), 1478–1489.
30. Gurley, B.J., Gardner, S.F., Hubbard, M.A., Williams, D.K., Gentry, W.B., Cui, Y., Ang, C.Y.W., Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: st. John's wort, garlic oil, Panax ginseng, and Ginkgo biloba. Drugs Aging 22:6 (2005), 525–539.
31. Gurley, B.J., Fifer, E.K., Gardner, Z., Pharmacokinetic herb-drug interactions (Part 2): drug interactions involving popular botanical detary supplements and their clinical relevance. Planta Med. 78 (2012), 1490–1514.
32. Gurley, B.J., Markowitz, J.S., Williams, D.K., Barone, G.W., Practical considerations when designing and conducting clinical pharmacokinetic herb-drug interaction studies. Int. J. Pharmacokinetics. 2:1 (2017), 57–69.
33. He, S.M., Chan, E., Zhou, S.F., ADME properties of herbal medicines in humans: evidence, challenges and strategies. Curr. Pharmaceut. Des. 17:4 (2011), 357–407.
34. Homma, M., Oka, K., Yamada, T., Niitsuma, T., Ihto, H., Takahashi, N., A strategy for discovering biologically active compounds with high probability in traditional Chinese herb remedies: an application of saiboku-to in bronchial asthma. Anal. Biochem. 202:1 (1992), 179–187.
35. Jia, W., Fan, T.P., Wang, X.N., Xie, G.X., The polypharmacokinetics of herbal medicines. Science 350 (2015), S76–S79.
36. Jordan, S.A., Cunningham, D.G., Marles, R.J., Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol. Appl. Pharmacol. 243 (2010), 198–216.
37. Karsch-Völk, M., Barrett, B., Linde, K., Echinacea for preventing and treating the common cold. J. Am. Med. Assoc. 6 (2015), 618–619.
38. Kaufman, D.W., Kelly, J.P., Rosenberg, L., Anderson, T.E., Mitchell, A.A., Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. J. Am. Med. Assoc. 287 (2002), 337–344.
39. Korobkova, E.A., Effect of natural polyphenols on CYP metabolism: implications for diseases. Chem. Res. Toxicol. 28 (2015), 1359–1390.
40. Kressmann, S., Biber, A., Wonnemann, M., Schug, B., Blume, H.H., Müller, W.E., Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations. J. Pharm. Pharmacol. 54:11 (2002), 1507–1514.
41. Lambert, J.D., Kennett, M.J., Sang, S., Reuhl, K.R., Ju, J., Yang, C.S., Hepatotoxicity of high oral dose (−)-epigallocatechin-3-gallate in mice. Food Chem. Toxicol. 48:1 (2010), 409–416.
42. Lan, K., Jia, W., An integrated metabolomics and pharmacokinetics strategy for multi-component drugs evaluation. Curr. Drug Metabol. 11 (2010), 105–114.
43. Lan, K., Xie, G., Jia, W., Towards polypharmacokinetics: pharmacokinetics of multicomponent drugs and herbal medicines using a metabolomics approach. Evid. Base. Compl. Alternat. Med., 2013, 2013 http://dx.doi.org/10.1155/2013/819147 819147.
44. Leach, M.J., Moore, V., Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst. Rev.(9), 2012, CD007244.
45. Letsyo, E., Jerz, G., Winterhalter, P., Lindigkeit, R., Beuerle, T., Incidence of pyrrolizidine alkaloids in herbal medicines from German retail markets: risk assessment and inplications to consumers. Phytother Res. 31 (2017), 1903–1909.
46. Liang, Y., Hao, H., Kanga, A., Xie, L., Xiea, T., Zhenga, X., Daia, C., Wanb, L., Shenga, L., Wanga, G., Qualitative and quantitative determination of complicated herbal components by liquid chromatography hybrid ion trap time-of-flight mass spectrometry and a relative exposure approach to herbal pharmacokinetics independent of standards. J. Chromatogr. A 30 (2010), 4971–4979.
47. Ma, G., Bavadekar, S.A., Davis, Y.M., Lalchandani, S.G., Nagmani, R., Schaneberg, B.T., Khan, I.A., Feller, D.R., Pharmacological effects of ephedrine alkaloids on human 1- and 2-adrenergic receptor subtypes. J. Pharmacol. Exp. Therapeut. 322 (2007), 214–221.
48. Mahady, G.B., Low Dog, T., Barrett, M.L., Chavez, M.L., Gardiner, P., Ko, R., Marles, R.J., Pellicore, L.S., Giancaspro, G.I., Sarma, D.N., United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 15:4 Pt 1 (2008), 628–638.
49. Mauri, P., De Palma, A., Pozzi, F., Basilico, F., Riva, A., Morazzoni, P., Bombardelli, E., Rossoni, G., LC-MS characterization of terpene lactones in plasma of experimental animals treated with Ginkgo biloba extracts Correlation with pharmacological activity. J. Pharmaceut. Biomed. Anal. 40:3 (2006), 763–768.
50. Mauri, P., Simonetti, P., Gardana, C., Minoggio, M., Morazzoni, P., Bombardelli, E., Pietta, P., Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts. Rapid Commun. Mass Spectrom. 15:12 (2001), 929–934.
51. Mercado-Feliciano, M., Cora, M.C., Witt, K.L., Granville, C.A., Hejtmancik, M.R., Fomby, L., Knostman, K.A., Ryan, M.J., Newbold, R., Smith, C., Foster, P.M., Vallant, M.K., Stout, M.D., An ethanolic extract of black cohosh causes hematological changes but not estrogenic effects in female rodents. Toxicol. Appl. Pharmacol. 263:2 (2012), 138–147.
52. National Toxicology Program (NTP), NTP technical report on the toxicology and carcinogenesis studies of kava kava extract (CAS No. 9000-38-8) in F344/N rats and B6C3F1 mice. Natl. Toxicol. Progr. Tech. Rep., 571, 2012.
53. National Toxicology Program (NTP), NTP technical report on the toxicology and carcinogenesis studies of ginkgo biloba extract (CAS No. 90045-36-6) in F344/N rats and B6C3F1/N mice. Natl. Toxicol. Progr. Tech. Rep., 578, 2013.
54. National Toxicology Program (NTP), Toxicology studies of green tea extract in F344/NTac rats and B6C3F1/N mice and Toxicology and carcinogenesis studies of green tea extract in Wistar Han[Crl:Wi(Han)] rats and B6C3F1/N mice. Natl. Toxicol. Progr. Tech. Rep., 585, 2014.
55. Navarro, V.J., Bonkovsky, H.L., Hwang, S.I., Vega, M., Barnhart, H., Serrano, J., Catechins in dietary supplements and hepatotoxicity. Dig. Dis. Sci. 58 (2013), 2682–2690.
56. Picking, D., The global regulatory framework for medicinal plants. Pharmacognosy:Fundamentals. Appl. Strat., 2017, 663–675.
57. Rahmani, A.H., Al shabrmi, F.M., Allemailem, K.S., Aly, S.M., Khan, M.A., Implications of green tea and its constituents in the prevention of cancer via the modulation of cell signalling pathway. BioMed Res. Int., 2015, 2015, 925640.
58. Rashrash, M., Schommer, J.C., Brown, L.M., Prevalence and predictors of herbal medicine use among adults in the United States. J. Patient Exp. 4:3 (2017), 108–113.
59. Rider, C.V., Nyska, A., Cora, M.C., Kissling, G.E., Smith, C., Travlos, G.S., Hejtmancik, M.R., Fomby, L.M., Colleton, C.A., Ryan, M.J., Kooistra, L., Morrison, J.P., Chan, P.C., Toxicity and carcinogenicity studies of Ginkgo biloba extract in rat and mouse: liver, thyroid, and nose are targets. Toxicol. Pathol. 42 (2014), 830–843.
60. Roberts, G.K., Gardner, D., Foster, P.M., Howard, P.C., Lui, E., Walker, L., van Breemen, R.B., Auerbach, S.S., Rider, C., Finding the bad actor: challenges in identifying active constituents in botanical dietary supplements. Food Chem. Toxicol., 2018 in revision.
61. Roe, A.L., Paine, M.F., Gurley, B.J., Brouwer, K.R., Jordan, S., Griffiths, J.C., Assessing natural product-drug interactions: an end-to-end safety framework. Regul. Toxicol. Pharmacol., 76, 2016, 106.
62. Rossi, R., Basilico, F., Rossoni, G., Riva, A., Morazzoni, P., Mauri, P.L., Liquid chromatography/atmospheric pressure chemical ionization ion trap mass spectrometry of bilobalide in plasma and brain of rats after oral administration of its phospholipidic complex. J. Pharmaceut. Biomed. Anal. 50:2 (2009), 224–227.
63. Russmann, S., Lauterburg, B.H., Helbling, A., Kava hepatotoxicity. Ann. Intern. Med. 135 (2001), 68–69.
64. Russmann, S., Barguil, Y., Cabalion, P., Kritsanida, M., Duhet, D., Lauterburg, B.H., Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur. J. Gastroenterol. Hepatol. 15 (2003), 1033–1036.
65. Sakamoto, Y., Mikuriya, H., Tayama, K., Takahashi, H., Nagasawa, A., Yano, N., Yuzawa, K., Ogata, A., Aoki, N., Goitrogenic effects of green tea extract catechins by dietary administration in rats. Arch. Toxicol. 10 (2001), 591–596.
66. Schmidt, M., Schmitz, H.-J., Baumgart, A., Guédon, D., Netsch, M.I., Kreuter, M.H., Schmidlin, C.B., Schrenk, D., Toxicity of green tea extracts and their constituents in rat hepatocytes in primary culture. Food Chem. Toxicol. 43:2 (2005), 307–314.
67. Shipkowski, K.A., Betz, J.M., Birnbaum, L.S., Bucher, J.R., Coates, P.M., Hopp, D.C., Mackay, D., Oketch-Rabah, H., Walker, N.J., Welch, C., Rider, C.V., Naturally complex: perspectives and challenges associated with botanical dietary supplement safety assessment. Food Chem. Toxicol., 2018 https://doi.org/10.1016/j.fct.2018.04.007.
68. Smith, T., Kawa, K., Eckl, V., Morton, C., Strednev, R., Herbal supplement sales in US increase 7.7% in 2016. Consumer preferences shifting toward ingredients with general wellness benefits, driving growth of adaptogens and digestive health products. HerbalGram 115 (2017), 56–65.
69. Snitz, B.E., O'merrera, E.S., Carlson, M.C., Arnold, A.M., Ives, D.G., Rapp, S.R., Saxton, J., Lopez, L., Dunn, L.O., Sink, K.M., Dekosky, S.T., Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for preventing cognitive decline in older adults. A randomized trial. J. Am. Med. Assoc. 302 (2009), 2663–2670.
70. Sprouse, A.A., van Breemen, R.B., Pharmacokinetic interactions between drugs and botanical dietary supplements. Drug Metab. Dispos. 44 (2015), 162–171.
71. Sitges, M., Aldana, B.I., Reed, R.C., Effect of the anti-depressant sertraline, the novel anti-seizure drug vinpocetine and several conventional antiepileptic drugs on the epileptiform EEG activity induced by 4-aminopyridine. Neurochem. Res. 41 (2016), 1365–1374.
72. Tsai, H.H., Lin, H.W., Simon Pickard, A., Tsai, H.Y., Mahady, G.B., Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. Int. J. Clin. Pract. 66 (2012), 1056–1078.
73. Ude, C., Paulke, A., Nöldner, M., Schubert-Zsilavecz, M., Wurglics, M., Plasma and brain levels of terpene trilactones in rats after an oral single dose of standardized Ginkgo biloba extract EGb 761. Planta Med. 77:3 (2011), 259–264.
74. Ude, C., Schubert-Zsilavecz, M., Wurglics, M., Ginkgo biloba extracts: a review of the pharmacokinetics of the active ingredients. Clin. Pharmacokinet. 52 (2013), 727–749.
75. Unger, M., Pharmacokinetic drug interactions involving Ginkgo biloba. Drug Metab. Rev. 45:3 (2013), 353–385.
76. U.S. Department of Health and Human Services (DHHS), Dietary Supplement Health and Education Act. 1994, National Institutes of Health Office of Dietary Supplements http://ods.od.nih.gov/About/dshea_ wording.aspx (accessed Februrary 20, 2017).
77. van Beek, T.A., Chemical analysis of Ginkgo biloba leaves and extracts. J. Chromatogr. A 967 (2002), 21–55.
78. van Breemen, R.B., Fong, H.H., Farnsworth, N.R., The role of quality assurance and standardization in the safety of botanical dietary supplements. Chem. Res. Toxicol. 20:4 (2007), 577–582.
79. van Breemen, R.B., Liang, W., Banuvar, S., Shulman, L.P., Pang, Y., Tao, Y., Nikolic, D., Krock, K.M., Fabricant, D.S., Chen, S.-N., Hedayat, S., Bolton, J.L., Pauli, G.F., Piersen, C.E., Krause, E.C., Geller, S.E., Farnsworth, N.R., Pharmacokinetics of 23-epi-26-deoxyactein in women after oral administration of a standardized extract of black cohosh. Clin. Pharmacol. Ther. 87:2 (2010), 219–225.
80. Waidyanatha, S., Toy, H., South, N., Gibbs, S., Mutlu, E., Burback, B., McIntyre, B.S., Catlin, N., Systemic exposure of vinpocetine in pregnant Sprague Dawley rats following repeated oral exposure: an investigation of fetal transfer. Toxicol. Appl. Pharmacol. 1:338 (2018), 83–92.
81. Wang, Y.L., Liang, Y.Z., Chen, B.M., He, Y.K., Li, B.Y., Hu, Q.N., LC-DAD-APCI-MS-based screening and analysis of the absorption and metabolite components in plasma from a rabbit administered an oral solution of danggui. Anal. Bioanal. Chem. 383:2 (2005), 247–254.
82. Wang, P., Liang, Y.Z., Zhou, N., Chen, B.M., Yi, L.Z., Yu, Y., Yi, Z.B., Screening and analysis of the multiple absorbed bioactive components and metabolites of Dangguibuxue decoction by the metabolic fingerprinting technique and liquid chromatography/diode-array detection mass spectrometry. Rapid Commun. Mass Spectrom. 21:2 (2007), 99–106.
83. Wang, X.J., Sun, W.J., Sun, H., Lv, H.T., Wu, Z.M., Wang, P., Liu, L., Cao, H.X., Analysis of the constituents in the rat plasma after oral administration of Yin Chen Hao Tang by UPLC/Q-TOFMS/MS. J. Pharmaceut. Biomed. Anal. 46:3 (2008), 477–490.
84. Wang, L., Wang, Z., Wo, S., Lau, C.B., Chen, X., Huang, M., Lee, V.H., Chow, M.S., Zuo, Z., A bio-activity guided in vitro pharmacokinetic method to improve the quality control of Chinese medicines, application to Si Wu Tang. Int. J. Pharm. 406 (2011), 99–105.
85. Woelkart, K., Feizlmayr, E., Dittrich, P., Beubler, E., Pinl, F., Suter, A., Bauer, R., Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother Res. 24:3 (2010), 445–450.
86. Xie, G., Zhao, A., Zhao, L., Chen, T., Chen, H., Qi, X., Zheng, X., Ni, Y., Cheng, Y., Lan, K., Yao, C., Qiu, M., Jia, W., Metabolic fate of tea polyphenols in humans. J. Proteome Res. 11 (2012), 3449–3457.
87. Zhang, J.L., Cui, M., He, Y., Yu, H.L., Guo, D.A., Chemical fingerprint and metabolic fingerprint analysis of Danshen injection by HPLC-UV and HPLC-MS methods. J. Pharm.Biomed. Anal. 36:5 (2005), 1029–1035.
88. Zheng, B., Teng, L., Xing, G., Bi, Y., Yang, S., Hao, F., Yan, G., Wang, X., Lee, R.J., Teng, L., Xi, J., Proliposomes containing a bile salt for oral delivery of Ginkgo biloba extract: formulation optimization, characterization, oral bioavailability and tissue distribution in rats. Eur. J. Pharmaceut. Sci. 77 (2015), 254–264.